Australia's Dimerix hits 7-month high on $4.8 billion sale

Shares of Dimerix DXB.AX rise as much as 12.5% to A$0.63, its highest level in seven months

Stock touches its biggest intraday pct gain in six months, if gains hold

Biotech co says U.S. listed biotech firm, BioMarin Pharmaceutical BMRN.O to acquire co's U.S. commercial licensing partner, Amicus Therapeutics for $4.8 billion

Amicus Therapeutics is a biopharma co, licensing DXB's drug, DMX-200, for U.S. market to treat rare kidney diseases

Stock up 80.89% YTD, including session's moves